KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Operating Leases (2019 - 2025)

Historic Operating Leases for Pacific Biosciences Of California (PACB) over the last 7 years, with Q3 2025 value amounting to $54.3 million.

  • Pacific Biosciences Of California's Operating Leases rose 22067.56% to $54.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.3 million, marking a year-over-year increase of 22067.56%. This contributed to the annual value of $14.9 million for FY2024, which is 5281.28% down from last year.
  • Latest data reveals that Pacific Biosciences Of California reported Operating Leases of $54.3 million as of Q3 2025, which was up 22067.56% from $52.1 million recorded in Q2 2025.
  • Pacific Biosciences Of California's 5-year Operating Leases high stood at $54.3 million for Q3 2025, and its period low was $14.9 million during Q4 2024.
  • Its 5-year average for Operating Leases is $38.4 million, with a median of $39.0 million in 2023.
  • Its Operating Leases has fluctuated over the past 5 years, first tumbled by 5281.28% in 2024, then surged by 22067.56% in 2025.
  • Pacific Biosciences Of California's Operating Leases (Quarter) stood at $50.0 million in 2021, then decreased by 17.81% to $41.1 million in 2022, then dropped by 23.04% to $31.6 million in 2023, then crashed by 52.81% to $14.9 million in 2024, then surged by 264.09% to $54.3 million in 2025.
  • Its Operating Leases was $54.3 million in Q3 2025, compared to $52.1 million in Q2 2025 and $52.9 million in Q1 2025.